Drug Monograph
MVASI
Bevacizumab-awwb 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Your search for bevacizumab returned 137 results
Drug Monograph
ZIRABEV
Bevacizumab-bvzr 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Drug Monograph
AVASTIN
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Drug News
Review Compares Bevacizumab vs. Ranibizumab for Macular Degeneration
The systemic safety of bevacizumab appears to be similar to that of ranibizumab as intravitreal therapy for neovascular age-related macular degeneration (AMD).
ASCO 2011
ICON7 Trial Shows Bevacizumab Increases Survival in Women with Newly Diagnosed Ovarian Cancer
The addition of bevacizumab to carboplatin and paclitaxel chemotherapy for the first-line treatment of women with ovarian cancer may offer benefit compared with standard chemotherapy alone, particularly for patients with more aggressive disease, investigators noted in a presentation during the American Society of Clinical Oncology's 2011 Annual Meeting.
Drug News
Adjuvant Bevacizumab Ups Survival in Cervical Cancer
Adjuvant bevacizumab increases overall survival in cervical cancer and improves progression-free survival in glioblastoma.
News
Bevacizumab Ups Progression-Free Survival in Ovarian Cancer
For women with ovarian cancer, the addition of bevacizumab to standard chemotherapy results in significantly improved progression-free survival (PFS).
Drug News
Bevacizumab Safe, Stable for Multiple Dosing From Single Vial
No evidence of infection, inflammation when bevacizumab is stored at 4 Celsius for a week
News
Endophthalmitis Risk May Not Be Higher With Bevacizumab After All
Ophthalmic injections of bevacizumab exhibited no greater risk of endophthalmitis than injections of ranibizumab, according to a new study published in JAMA Ophthalmology.
News
ASCO: Continuing Avastin With 2nd-Line Chemo Ups Survival
Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who have progressed after discontinuation of first-line bevacizumab and chemotherapy.
